Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

The ORAL Surveillance trial found that patients with rheumatoid arthritis (RA) aged ≥50 years with ≥1 additional cardiovascular (CV) risk factor had an increased risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi).1 A post hoc analysis indicated that the increased risk of MACE with tofacitinib versus TNFi was apparent primarily in patients with a history of atherosclerotic CV disease (ASCVD), that is, pre-existing coronary artery, cerebrovascular or peripheral artery disease.2

Excess risk of MACE was not identified in the wider tofacitinib RA clinical trial programme (consisting of 21 phase 1–3b and 2 long-term extension studies, hereafter collectively referred to as P123LTE).1 To better understand the results from ORAL Surveillance vs P123LTE, we: (1) applied the ORAL Surveillance CV risk-enrichment criteria to P123LTE (patients who received ≥1 tofacitinib dose) to create a CV risk-enriched P123LTE cohort (P123LTE-CV+; patients aged ≥50 years who had ≥1 additional CV risk factor (current smoker, hypertension, high-density lipoprotein cholesterol <40 mg/dL, diabetes mellitus, history of coronary artery disease)) and (2) assessed MACE incidence rates (IRs) in all patients, and separately in patients with and without history of ASCVD, in P123LTE and P123LTE-CV+.

P123LTE included 7964 patients; of these, 3125 (39.2%) were included in P123LTE-CV+. MACE data were summarised by tofacitinib dose (average 5 or 10 mg two times per day, based on an average total daily dose of <15 or ≥15 mg, respectively). IRs (patients with unique events/100 patient-years) with 95% CI were evaluated for adjudicated MACE and compared with previously published data from ORAL Surveillance.1,2 Adjudication of MACE was performed concurrently in phase 3 studies and retrospectively in phases 1 and 2 studies. Baseline CV risk profiles of P123LTE and P123LTE-CV+ were determined as previously described.2 Briefly, patients were grouped according to history of ASCVD, and patients with no history of ASCVD were further grouped by categories of predicted 10-year risk of MACE (high ≥20%), intermediate (7.5% to <20%), borderline (5% to <7.5%) and low (≤5%) risk), per the ASCVD equations calculator3 with a 1.5-multiplier applied.3

The proportion of patients with a history of ASCVD was higher in ORAL Surveillance (15%) than in P123LTE-CV+ (8%) or P123LTE (4%). Otherwise, the baseline CV risk profile of P123LTE-CV+ was similar to that of ORAL Surveillance (figure 1A).2 Mean baseline disease activity was high across cohorts (figure 1B). MACE IRs were highest in ORAL Surveillance followed by P123LTE-CV+ and P123LTE (figure 1B). However, when comparing the patients without history of ASCVD in P123LTE-CV+ and ORAL Surveillance, MACE IRs were similar (figure 1C). There were relatively few patients with history of ASCVD in P123LTE-CV+ and few MACE. Accordingly, due to wide 95% CI for the IRs, differences comparing P123LTE-CV+ and ORAL Surveillance were difficult to interpret (figure 1D).

In ORAL Surveillance, markedly higher MACE IRs were reported in tofacitinib-treated patients with history of ASCVD than in patients who had CV risk factors but no history of ASCVD.2 Also, excess risk of MACE with tofacitinib vs TNFi was apparent primarily in patients with history of ASCVD.2 Data from the wider tofacitinib clinical trial programme did not indicate increased risk of MACE compared with placebo or bDMARDs3 6; however, the comparative analyses were limited by smaller samples and shorter exposure than ORAL Surveillance and were not enriched for CV risk.

Results presented here suggest that an important difference between P123LTE and ORAL Surveillance was the proportion of patients with a history of ASCVD (4% and 15%, respectively). While the mechanism and generalisability of these findings require further study, they provide important context regarding the CV safety of tofacitinib in patients without a history of ASCVD.

Maxime Dougdas 1, 2, 3 Christina Charles-Schoeman, 3 Zoltan Szekanetz 4, 4 Jon T Giles, 6 Steven R Ytterberg, 6 Deepak L Bhatt, 7 Gary G Koch, 8 Ivana Vrnic, 9 Joseph Wu, 10 Gunshwan Wang, 10 Kenneth Kwok, 11 Sujatha Menon, 12 Carol A Connell 10 Arne Yndestad, 12 Jose L Rivas, 13 Maya H Buch 14, 15
1 Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France
2 INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France
3 Division of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA
4 Division of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
5 Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
6 Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA
7 Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York, USA
8 Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
9 Pfizer Ltd, Tadworth, UK
10 Pfizer Inc, Groton, Connecticut, USA
11 Pfizer Inc, New York, New York, USA
12 Pfizer Inc, Oslo, Norway
13 Pfizer SLU, Madrid, Spain
14 Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermalological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
15 NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

Correspondence to Professor Maxime Dougdas, Hôpital Cochin, Université de Paris, Paris, France; maxime.dougdas@aphp.fr

Handling editor Josef S Smolen

Acknowledgements Select data in this letter were previously presented at EULAR Congress 2022 (Dougdas M, Charles-Schoeman C, Szekanetz Z, et al. Ann Rheum Dis 2022;81[Suppl 1]:175–6). The authors would like to thank the patients, investigators and study teams involved in the tofacitinib clinical trial programme. The authors would like to thank Hyeyin Jo and Annette Szuemski from Sysco Health for contributing to the statistical analyses.

Contributors SRY, DLB, JW, CW, KK, CAC and AY conceived or designed the study and data analyses. KK acquired the data. CC-S, JTG, SRY, DLB, JW, CW, KK and AY analysed the data. All authors had access to the data, were involved in interpretation of data, and reviewed and approved the letter’s content before submission.

Funding This study was sponsored by Pfizer. Medical writing support, under the direction of the authors, was provided by Julia King, PhD, CMC Connect, a division of IPG Health Medical Communications, and was funded by Pfizer, New York, New York, USA, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022;175:1298–304).

Disclosure The views expressed in this article are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health.

Competing interests MD has acted as a consultant for AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer Inc, Roche and UCB; and has received grant/research support from AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer Inc, Roche and UCB. CC-S has acted as a consultant for AbbVie, Gilead Sciences, Pfizer Inc and Regeneron-Sanofi; and has received grant/research support from...
Figure 1  Risk of MACE in P123LTE, P123LTE-CV+, and ORAL Surveillance. (A) Baseline risk profiles. Patients without history of ASCVD were categorised according to their 10-year risk of MACE, per the ASCVD-PCE risk calculator4 with a 1.5-multiplier applied.5 The proportions of patients who had no history of ASCVD and were missing ASCVD-PCE risk category data are not shown (P123LTE: average tofacitinib 5 mg two times per day, n=42 (1.2%); average tofacitinib 10 mg two times per day per day n=321 (8.5%); P123LTE-CV+: average tofacitinib 5 mg two times per day, n=18 (1.3%); average tofacitinib 10 mg two times per day, n=130 (9.1%); ORAL Surveillance: tofacitinib 5 mg two times per day, n=17 (1.2%); tofacitinib 10 mg two times per day, n=18 (1.2%).) (B–D) IRs and 95% CIs (number of patients with first events per 100 PY) for MACE in: (B) all patients; (C) patients with no history of ASCVD; and (D) patients with history of ASCVD. For patients randomised to the tofacitinib 10 mg two times per day group in ORAL Surveillance who had their dose of tofacitinib reduced to 5 mg two times per day, the data collected after patients were switched to tofacitinib 5 mg two times per day were counted in the tofacitinib 10 mg two times per day group. Data for P123LTE cohorts included patients from RA studies (NCT01262118, NCT01484561, NCT00147498, NCT000413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT0109864, NCT01359150, NCT02174587, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT0109688, NCT02281552, NCT02187055, NCT02831855, NCT00413699, NCT00661661) with the CV adjudication process applied after 25 February 2009. Data from ORAL Surveillance (NCT02092467) have been published.1 2 *One patient included in the overall analyses was excluded from the analyses by CV risk history due to an inactive Standardised MedDRA Query. †Treatment exposure was assessed in P123LTE as the time between first and last tofacitinib doses (including patients in studies prior to 25 February 2009 with no CV adjudication) and in ORAL Surveillance as the time from randomisation to last contact. ASCVD, atherosclerotic cardiovascular disease; BID, two times per day; CDAI, Clinical Disease Activity Index; CV, cardiovascular; HxASCVD, history of ASCVD; IR, incidence rate; MACE, major adverse CV events; n, number of patients with event; N, number of evaluable patients; P123LTE, Phase 1–3b/4 and long-term extension studies; P123LTE-CV+, CV risk-enriched population of P123LTE; PCE, pooled cohort equations; PY, patient-years; RA, rheumatoid arthritis.
Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Upon request, and subject to review, Pfizer Inc will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer Inc may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results-for-more-information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.


Received 27 September 2022
Accepted 6 December 2022
Published Online First 31 January 2023


ORCID iDs
Maxime Dougas http://orcid.org/0000-0003-3009-6229
Zoltán Szekanecz http://orcid.org/0000-0002-7794-6844
Maya H Buc http://orcid.org/0000-0002-8962-5642

REFERENCES